{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-25-000014","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.881621+00:00","generated_at":"2026-05-28T03:42:46.638456+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immuneering reports 50% ORR in Phase 2a of IMM-1-104/mFFX; raises $13.7M via ATM","bullets":["As of Jan 6, 2025, 3 of 6 evaluable patients achieved partial response, 3 stable disease; 50% ORR per RECIST.","IMM-1-104 with mFFX generally well tolerated; 3 partial responders and 1 stable disease patient remain on treatment.","Raised net proceeds of $13.7M in January 2025 through at-the-market equity offering program."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-25-000014","json":"https://secwatch.observer/filing/0001790340-25-000014.json","markdown":"https://secwatch.observer/filing/0001790340-25-000014.md","text":"https://secwatch.observer/filing/0001790340-25-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000014/0001790340-25-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000014/imrx-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:42:46.638456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}